BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

With 11 days to go before liso-cel’s PDUFA date, FDA has yet to inspect one of two cell therapy facilities where the Bristol Myers Squibb CAR T is being manufactured, signaling a possible delay...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead program for blood cancer after it reached the IND stage. Now, the...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | Mar 17, 2020
Product Development

Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal

...designed to bind FOXP3 on the Treg and CD3 on effector T cells, drawing the two cells...
BioCentury | Jan 17, 2020
Company News

BioNTech finds its U.S. operations hub through takeout of struggling Neon

BioNTech added both a new neoantigen program and a Boston-based operations hub on Thursday through the acquisition of Neon -- a deal for pennies on the dollar. The all-stock transaction will see BioNTech SE (NASDAQ:BNTX)...
BioCentury | Jan 14, 2020
Company News

Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer. The announcement follows a 200% gain for Adaptimmune Therapeutics plc...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
Items per page:
1 - 10 of 87
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Nov 6, 2020
Regulation

Pressure builds for Celgene payout as BMS faces possible liso-cel delay

With 11 days to go before liso-cel’s PDUFA date, FDA has yet to inspect one of two cell therapy facilities where the Bristol Myers Squibb CAR T is being manufactured, signaling a possible delay...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead program for blood cancer after it reached the IND stage. Now, the...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | Mar 17, 2020
Product Development

Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal

...designed to bind FOXP3 on the Treg and CD3 on effector T cells, drawing the two cells...
BioCentury | Jan 17, 2020
Company News

BioNTech finds its U.S. operations hub through takeout of struggling Neon

BioNTech added both a new neoantigen program and a Boston-based operations hub on Thursday through the acquisition of Neon -- a deal for pennies on the dollar. The all-stock transaction will see BioNTech SE (NASDAQ:BNTX)...
BioCentury | Jan 14, 2020
Company News

Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer. The announcement follows a 200% gain for Adaptimmune Therapeutics plc...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
Items per page:
1 - 10 of 87